HOME >> MEDICINE >> NEWS
Better survival seen for early breast cancer patients switched from tamoxifen to Aromasin

ATLANTA, June 3, 2006 New data from the Intergroup Exemestane Study (IES) showed for the first time today that hormone sensitive postmenopausal early breast cancer patients who switched to Aromasin after 2 to 3 years of tamoxifen were 17% more likely to be alive and were 25% less likely to have their cancer return than patients who continued on tamoxifen for a full 5 years of therapy.

"Exemestane is the only anti-hormonal therapy that has been shown to demonstrate improved overall survival over tamoxifen alone," said Lead Investigator Professor Charles Coombes, director of cancer medicine, Imperial College, London. These significant survival benefits were seen in patients who are considered hormone sensitive, which represents 97% of the study population. Although not statistically significant in the intent to treat population, 15% of patients taking Aromasin were more likely to be alive versus those that continued on tamoxifen. These new findings were based on nearly 5 years of follow-up after randomization in the IES trial. IES was a large randomized double blind multinational trial of postmenopausal women with early breast cancer which was designed to compare the clinical benefits of switching 2352 patients to Aromasin after 2 to 3 years of tamoxifen versus continuing 2372 patients on tamoxifen for a full 5 years of therapy. The 5 year follow-up time includes a period of observation lasting over 2 years after completion of all treatment.

Earlier results of the IES trial, which led to US FDA and European regulatory approvals of Aromasin for treatment of early breast cancer, found that postmenopausal hormone receptor positive patients, which represented 85% of all patients in the trial, who switched to Aromasin reduced their risk of breast cancer recurring by 35% versus patients who stayed on tamoxifen for 5 years. At the earlier time point, a difference in overall survival had not been seen.

Breast cancer is one of the most comm
'"/>


3-Jun-2006


Page: 1 2 3

Related medicine news :

1. Better mobility keeps seniors healthier
2. Better insight into brain anatomical structures
3. Better health twice as likely for nonsmokers who live and work with smoking restrictions
4. Better designed roadway intersections can boost older drivers performance
5. Better strategies for osteoporosis prevention and therapy
6. Better review of new technology is needed to reduce health costs
7. Better training needed to reduce emergency caesareans
8. Better after-school snack choices boost nutrition for low-income kids, UC Davis research confirms
9. Outcomes of patients in trials; Better blood pressure treatment; Snake bites, and more
10. Better regulation needed for ethical research in Africa
11. Better procedures needed on care of prisoners in hospitals

Post Your Comments:
(Date:3/5/2015)... For PASCHA Chocolate, less is more. ... the robust flavor of the cacao bean bursts through ... is free from peanuts, nuts, dairy, soy, eggs, fish, ... 6th- 8th at Expo West., ,    NEW PASCHA ... broken new ground with their New PASCHA Make Me ...
(Date:3/5/2015)... Minn. (PRWEB) March 05, 2015 ... invites healthcare organizations to participate in its 2015 ... data from executive and director-level positions, and the ... , Last year’s report featured data on 60 ... independent children’s healthcare organizations and 7 subsidiary children’s ...
(Date:3/5/2015)... March 05, 2015 Leading nutritional supplement ... week’s Arnold Sports Festival and Arnold Fitness EXPO ... Metabolic Nutrition will host a display booth featuring free ... E.S.P. and its highly-popular, class-leading fat burner Synedrex. The ... unique recipes that utilize its top-of-the-line supplements and miniature ...
(Date:3/5/2015)... Indialantic, FL (PRWEB) March 05, 2015 ... sports nutrition products, is pleased to offer reformulated Millennium ... official website, Millennium 500 is a German grade creatine ... muscle hydration, promote muscle recovery, and aid with overall ... occurring compound that acts as a reserve energy source ...
(Date:3/5/2015)... Jordan Valley Medical Center is now utilizing ... for sudden cardiac arrest. When a patient wears this ... any life-threatening abnormalities. If an abnormal heart rhythm is ... a treatment shock to restore normal rhythm to the ... Medical Center and the Heart and Lung Institute of ...
Breaking Medicine News(10 mins):Health News:PASCHA Allergen Free Organic Chocolate to Appear at Natural Products Expo West March 6-8, 2015 2Health News:Participation Is Now Open For INTEGRATED Healthcare Strategies 2015 Children’s Hospitals Executive Compensation Survey 2Health News:Metabolic Nutrition Exhibiting at 2015 Arnold Sports Festival and Fitness EXPO This Week 2Health News:Nutrition Leaders Offers Reformulated Millennium 500 German Grade Creatine 2Health News:New Technology Behind LifeVest® Wearable Defibrillator Saves the Life of Utah Man in Cardiac Arrest 2Health News:New Technology Behind LifeVest® Wearable Defibrillator Saves the Life of Utah Man in Cardiac Arrest 3
(Date:3/5/2015)... , Mar. 05, 2015 Research and Markets ... the "India Pharma Outlook 2015: Accelerating growth to ... beyond Generics" report to their offering. ... slump in the 2013 caused by the market,s reaction ... is expected to continue to be healthy, as the ...
(Date:3/5/2015)... N.J. , March 5, 2015  ContraVir Pharmaceuticals, ... focused on the development and commercialization of targeted antiviral ... 27 th Annual ROTH Conference, to be held ... James Sapirstein , Chief ... business during his live presentation and will be available ...
(Date:3/5/2015)... , Mar. 05, 2015 Research and Markets ... addition of Jain PharmaBiotech,s new report "Therapeutic ... to their offering. This report ... specialty, aimed at improving patient care by monitoring ... the dose of drugs for improving outcome. TDM ...
Breaking Medicine Technology:India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 2India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 3ContraVir to Present at 27th Annual ROTH Conference 2Global Therapeutic Drug Monitoring Report 2015 - Technologies, Markets, and Companies Analysis 2014-2024 2
Cached News: